Jorge Willian Leandro Nascimento

Prof. Dr. Jorge Willian Leandro Nascimento

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ARAline C. Ribeiro
Aline C. Ribeiro
PGPâmela S. A. S. Gerheim
Pâmela S. A. S. Gerheim
JCJúlio Chebli
Júlio Chebli
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento
PPPriscila de F. Pinto
Priscila de F. Pinto
This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy. The therapeutic monitoring of the metabolites 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine (6-MMP) is proposed to optimize treatment and minimize AEs. Patients with higher 6-TGN levels tend to have better clinical responses, while elevated 6-MMP levels are linked to hepatotoxicity. Genotyping for TPMT before or during treatment initiation is suggested to tailor dosing strategies and enhance treatment efficacy while reducing the risk of myelosuppression. In conclusion, this study highlights the importance of considering genetic variations and metabolite levels in optimizing thiopurine therapy for IBD patients, focusing on balance therapeutic efficacy with the prevention of adverse effects and contributing to personalized treatment and better patient outcomes.

17 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLara Soares Aleixo de Carvalho
Lara Soares Aleixo de Carvalho
VSVINICIUS Carius de Souza
VINICIUS Carius de Souza
VRVinícius C. Rodrigues
Vinícius C. Rodrigues
ARAline Correa Ribeiro
Aline Correa Ribeiro
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento
Ademar Alves Da Silva FilhoAdemar Alves Da Silva Filho
Ademar Alves Da Silva Filho
Schistosomiasis, caused by parasites of the genus Schistosoma, is a neglected disease with high global prevalence, affecting more than 240 million people in several countries. Praziquantel (PZQ) is the only drug currently available for the treatment. S. mansoni NTPDases (known as SmNTPDases, ATP diphosphohydrolases or ecto-apyrases) are potential drug targets for the discovery of new antischistosomal drugs. In this study, we screen NTPDases inhibitors from Centella erecta (Apiaceae) using an ultrafiltration combined UHPLC-QTOF-MS method and potato apyrase, identifying asiaticoside as one of the apyrase-binding compounds. After isolation of asiaticoside from C. erecta extract, we assessed its in vivo antischistosomal activities against Schistosoma mansoni worms and its in vitro enzymatic apyrase inhibition. Also, molecular docking analysis of asiaticoside against potato apyrase, S. mansoni NTPDases 1 and 2 were performed. Asiaticoside showed a significant in vitro apyrase inhibition and molecular docking studies corroborate with its possible actions in potato apyrase and S. mansoni NTPDases. In mice harboring a patent S. mansoni infection, a single oral dose of asiaticoside (400 mg/kg. p.o.) showed significantly in vivo antischistosomal efficacy, markedly decreasing the total worm load and egg burden, giving support for further exploration of apyrase inhibitors as antischistosomal agents.

1 July 2018 in Fitoterapia
Verified
Journal Article
Closed access
DMDalyara Mendonça de Matos
Dalyara Mendonça de Matos
MVMilainy Rocha Viana
Milainy Rocha Viana
MAMarcela Cristina de Oliveira Alvim
Marcela Cristina de Oliveira Alvim
LCLara Soares Aleixo de Carvalho
Lara Soares Aleixo de Carvalho
LLLaura Hora Rios Leite
Laura Hora Rios Leite
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento

1 January 2022 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
RNRodrigo José Lupatini Nogueira
Rodrigo José Lupatini Nogueira
RGRichard Michael Grazul
Richard Michael Grazul
AFAdemar Alves Da Silva Filho
Ademar Alves Da Silva Filho
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento

13 February 2018 in Journal of Basic and Clinical Physiology and Pharmacology
Verified
Journal Article
Closed access
PDF file
ESErnane C. de Souza
Ernane C. de Souza
DMDalyara M. Matos
Dalyara M. Matos
MVMilainy R. Viana
Milainy R. Viana
MAMarcela C.O. Alvim
Marcela C.O. Alvim
HBHerval L. Bonfante
Herval L. Bonfante
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento
Background: Dipyrone is a non-narcotic analgesic/antipyretic widely used in some countries but prohibited in others due to suspected risk of agranulocytosis. The primary goal of this study was to evaluate hematological alterations in healthy adult volunteers after treatment with dipyrone. Methods: The study enrolled 30 healthy volunteers of both genders, aged 19–37 years. They received tablets containing 500 mg of dipyrone sodium to be used four times daily for 7 consecutive days. Before the first administration, arterial pressure was measured and blood was collected in order to evaluate hematological baseline parameters. On the 8th day after the beginning of treatment, the volunteers had their blood pressure assessed once more and underwent a second blood draw. Total and specific leukocyte counts, creatinine, urea, aspartate aminotransferase (AST), alanine aminotransferase (ALT), erythrocytes, and platelets were quantitatively determined. Results: No statistically significant difference was observed among total or specific leukocyte counts. Number of platelets, erythrocytes, hemoglobin, and hematocrit decreased after treatment. Diastolic pressure, mean arterial pressure (MAP), and urea concentration declined, while creatinine, AST, and ALT showed no significant alterations. It is noteworthy that, even for parameters that showed statistically significant changes, the highest and lowest values remained within the normal ranges. Conclusions: Although dipyrone has historically been associated with agranulocytosis, leukocyte counts remained practically unchanged after oral administration of dipyrone. On the other hand, the present study adds evidence that dipyrone is able to produce statistically relevant decrease in number of platelets, erythrocytes, hemoglobin, and hematocrit in healthy adults, even after short-term treatment.

8 October 2014 in Drug Research
Verified
Journal Article
Closed access
PDF file
RBR. F. Boiati
R. F. Boiati
MMM. T. Manchini
M. T. Manchini
OJO. Jacobsen
O. Jacobsen
JBJ. G. dos Santos Batista
J. G. dos Santos Batista
JJJ. A. Silva Júnior
J. A. Silva Júnior
JNJorge Willian Leandro Nascimento
Jorge Willian Leandro Nascimento
Statins are cholesterol-lowering agents and some of them, like simvastatin, have anti-inflammatory effects. In this study, we evaluated the effect of atorvastatin on nitric oxide (NO) release, leukocytes levels and alveolar diameter related to the inflammatory process associated with elastase-induced emphysema in rats. 32 rats were divided into 4 groups, n=8: control (C), atorvastatin (A), emphysema (E), and emphysema+atorvastatin (EA). On day 0 (zero), groups C and A received intratracheal instillation of saline (0.2 ml), and groups E and EA received elastase (0.2 ml). Groups A and EA received atorvastatin (20 mg/kg) and C and E received vehicle, by gavage, for 25 days. Animals were euthanized, slices of lung stained and the alveolar diameters measured. Data obtained show that the treatment with atorvastatin (EA group) did not reduce the alveolar diameter (35.3 vs. 32.3), NO (2.7 vs. 3.0 μM) or the leukocyte count (111 vs. 136) compared with the E group, indicating that different statins, like simvastatin or atorvastatin, have different behavior in inflammatory processes like in elastase-induced development of emphysema in rats.